IP Verse

Graf Von Stosch competitive analysis

Loading summary...

Explore patent oppositions filed by Graf Von Stosch against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP3487881	Methods Of Treating New-Onset Plaque Type Psoriasis Using Il-17 Antagonists	NOVARTIS	May 21, 2025
EP2854831	Manufacture Of Degarelix	FERRING	Apr 10, 2025
EP4013385	Improved Lipid Nanoparticles For Delivery Of Nucleic Acids	ACUITAS THERAPEUTICS	Apr 1, 2025
EP3529360	Methods For Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Protein Reduction	NOVARTIS	Jan 17, 2025
EP3191120	Use Of Il-17 Antagonists To Inhibit The Progression Of Structural Damage In Psoriatic Arthritis Patients	NOVARTIS	Jan 10, 2025
EP3328416	Use Of C-Type Natriuretic Peptide Variants To Treat Skeletal Dysplasia	BIOMARIN PHARMACEUTICAL	Dec 13, 2024
EP3334747	Charged Depth Filtration Of Antigen-Binding Proteins	AMGEN	Jun 27, 2024
EP3373013	Method For Predicting The Off-Target Biding Of A Peptide Which Binds To A Target Peptide Presented By A Major Histocompatibility Complex	ADAPTIMMUNE	Apr 18, 2024
EP3191517	Cross Reactive Siglec Antibodies	INNATE PHARMA	Aug 3, 2021
EP2911684	Il-15R Alpha Forms, Cells Expressing Il-15R Alpha Forms, And Therapeutic Uses Of Il-15R Alpha And Il-15/Il-15R Alpha Complexes	ADMUNE THERAPEUTICS	Mar 19, 2020

Explore the latest publications and patents granted to Graf Von Stosch, showcasing their recent innovations and technological advancements.

Discover the latest PTAB cases involving Graf Von Stosch, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Graf Von Stosch with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
GRAF VON STOSCH	4	-	-	-
ACUITAS THERAPEUTICS	1	6	-	-
ADMUNE THERAPEUTICS	-	2	-	-
NOVARTIS	6	422	-	21